Anavex Life Sciences Corp.
NASDAQ:AVXL · NASDAQ Global Select
-$0.04 today
Vol 8.91M · Avg 1.39M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
-70.65%
Period High
$13.41
Period Low
$2.46
Latest
$2.73
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.25B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.38B
Absci Corporation
NASDAQ:ABSI
$1.13B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.06B
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$509.20M
Arvinas, Inc.
NASDAQ:ARVN
$489.72M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$470.41M
REGENXBIO Inc.
NASDAQ:RGNX
$423.92M
What is the latest AVXL filing?
The latest filing shown is 8-K dated May 22, 2026.
How many recent filings does AVXL have?
Intrinsic Alpha currently shows 20 recent filings for AVXL.
Explore More
Continue the stock analysis
Jump to another research area for this company.